Equities

Kuros Biosciences AG

Kuros Biosciences AG

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CHF)24.30
  • Today's Change1.90 / 8.48%
  • Shares traded291.52k
  • 1 Year change+531.17%
  • Beta1.1820
Data delayed at least 15 minutes, as of Nov 22 2024 16:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CHF
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments142429
Total Receivables, Net7.623.622.05
Total Inventory4.863.171.76
Prepaid expenses0.510.540.47
Other current assets, total----0
Total current assets273133
Property, plant & equipment, net2.642.322.45
Goodwill, net242933
Intangibles, net171923
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets718391
LIABILITIES
Accounts payable1.301.300.85
Accrued expenses7.934.963.42
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.580.420.32
Other current liabilities, total3.385.916.70
Total current liabilities131311
Total long term debt1.571.501.83
Total debt2.141.912.15
Deferred income tax--00.89
Minority interest------
Other liabilities, total--00.35
Total liabilities151414
SHAREHOLDERS EQUITY
Common stock3.683.663.28
Additional paid-in capital------
Retained earnings (accumulated deficit)536574
Treasury stock - common(0.02)(0.02)(0.02)
Unrealized gain (loss)------
Other equity, total------
Total equity576977
Total liabilities & shareholders' equity718391
Total common shares outstanding373733
Treasury shares - common primary issue0.020.020.02
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.